ORG Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

ORG Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30	Closed	-$270	–	1596
2025 Q2	$270	Hold	30	–	–	﹤0.01%	1455
2025 Q1	$217	Buy	+30	New	+$242	﹤0.01%	1337

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ORG Partners's BCRX Position: Q3 2025 in Review

ORG Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 30 shares — an estimated $270 sold.

ORG Partners first reported a position in BCRX in Q1 2025 and held it in 2 quarters. The position peaked at $270 in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

ORG Partners reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
ORG Partners sold 30 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $270.
ORG Partners first reported a position in BioCryst Pharmaceuticals in Q1 2025 and held it in 2 quarters.
ORG Partners's BioCryst Pharmaceuticals position peaked at $270 in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on ORG Partners's 13F filing for Q3 2025, filed 24 Oct 2025.